GGHC
ACHN

Gilder Gagnon Howe & Co’s Achillion Pharmaceuticals ACHN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-415,055
Closed -$5.08M – 292
2014
Q4 		$5.08M Sell
415,055
-2,815
-0.7% -$34.4K 0.08% 143
2014
Q3 		$4.17M Buy
+417,870
New +$3.88M 0.06% 155

Other funds holding ACHN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gilder Gagnon Howe & Co's ACHN Position: Q1 2015 in Review

Gilder Gagnon Howe & Co sold out of Achillion Pharmaceuticals (ACHN) in Q1 2015, closing a stake of 415,055 shares — an estimated $5.08M sold.

Gilder Gagnon Howe & Co first reported a position in ACHN in Q3 2014 and held it in 2 quarters. The position peaked at $5.08M in Q4 2014. 173 funds tracked by Wall St. Rank hold ACHN as of Q1 2015.

  • Gilder Gagnon Howe & Co reported no remaining Achillion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 415,055 Achillion Pharmaceuticals shares in Q1 2015, an estimated $5.08M.
  • Gilder Gagnon Howe & Co first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Achillion Pharmaceuticals position peaked at $5.08M in Q4 2014.
  • 173 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2015, filed 30 Apr 2015.